Search

Displaying results 3781 - 3790 of 5089 in total
  1. Drug

    Gatifloxacin

    go.drugbank.com/drugs/DB01044
    ApprovedInvestigationalWithdrawn

    The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence

    Mixtures: GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL), GATIPHARM - D® (GATIFLOXACINA 0.3% + DEXAMETASONA 0.1% SOLUCIÓN OFTÁLMICA ESTERIL)
  2. Drug

    Velufenacin

    go.drugbank.com/drugs/DB21473
    Investigational

    Velufenacin has a monoisotopic molecular weight of 362.12 Da. … Velufenacin is under investigation in clinical trial NCT05282069 (A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder).

  3. Drug

    Netarsudil

    go.drugbank.com/drugs/DB13931
    ApprovedInvestigational

    A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indicati...

  4. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company.

  5. Drug

    Gestrinone

    go.drugbank.com/drugs/DB11619
    Approved

    However, from 1982 this drug attracted increased interest due to significant therapeutic effects in the treatment endometriosis.

  6. Drug

    Renadirsen

    go.drugbank.com/drugs/DB19132
    Investigational

    Renadirsen is under investigation in clinical trial NCT04433234 (Long-term, Extension Study of Ds-5141b in Patients With Duchenne Muscular Dystrophy).

  7. Drug

    Beclamide

    go.drugbank.com/drugs/DB09011
    Experimental

    Beclamide (N-benzyl-B-chloropropionamide) is a no longer used drug that possesses anticonvulsant and sedative activity. It was studied in the 1950s for generalised tonic-clonic seizures but was not effective for absence seizures.

  8. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A178090] Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. … [A18262] This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which

  9. Drug

    ADU-S100

    go.drugbank.com/drugs/DB14722
    Investigational

    ADU-S100 (MIW815) is a synthetic cyclic dinucleotide (CDN) agonist (activator) of Stimulator of Interferon Genes (STING), a receptor crucial to activate the innate (endogenous) immune system. … ADU-S100 (MIW815) activates all known human and mouse STINGs, and effectively induces the expression of cytokines and chemokines, leading to a robust and durable antigen-specific T-cell mediated immune

    Salts: ADU-S100 sodiumSynonyms: ADU-S100 free acid
  10. Drug

    Satavaptan

    go.drugbank.com/drugs/DB14923
    Investigational

    Satavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).